EC Pharmacology and Toxicology

Introduction: Cytotoxic drug reconstitution is a key step in the therapeutic chain in oncology. It requires rigorous practices to ensure the safety of healthcare personnel, drug stability, and the efficacy of treatment administered to patients.

Methodology: A descriptive narrative review was conducted using PubMed databases, selecting articles published between 2018 and 2024. Inclusion criteria were studies on cytotoxic reconstitution practices, international recommendations, organizational, technical and safety aspects. Articles not available in full text or not in English/French language were excluded.

Results: Studies reveal a wide variability in the application of international recommendations. Automation, the use of laminar flow hoods, dual control, and closed systems are recommended practices but still unevenly implemented.

Discussion: Improving reconstitution conditions requires standardization of procedures, ongoing training of preparers, and the adoption of secure technologies. Budgetary, logistical, and human constraints remain major obstacles.

Conclusion: It is imperative to promote the harmonization of reconstitution practices at the national and international levels to optimize the quality and safety of the cytotoxic circuit.

 Keywords: Cytotoxic Drug Reconstitution; Oncology; Cytotoxic Circuit

1. Sayer J., et al. “Occupational exposure to cytotoxic drugs: a review of risk and control strategies”. Journal of Occupational Health 6 (2016): 514-521.
2. Lammers RL and Hall M. “Safety considerations in the preparation and administration of chemotherapy”. Pharmacology and Therapeutics 3 (2015): 169-178.
3. Antonini A and Mazzola P. “Closed-system transfer devices for the preparation of cytotoxic drugs: safety and effectiveness”. Journal of Oncology Pharmacy Practice 5 (2019): 1065-1071.
4. Roberts M and Adams M. “Workplace training for handling hazardous drugs”. American Journal of Health-System Pharmacy 8 (2018): 503-509.
5. Collet D and Boudrault M. “Challenges in cytotoxicity drug preparation in the hospital setting: A review”. Cancer Chemotherapy and Pharmacology 6 (2017): 1153-1161.
6. Thorne M and Gauthier T. “Automation in chemotherapy preparation: A review of current technology”. Journal of Pharmaceutical Innovation 4 (2020): 283-289.
7. Williams F., et al. “Errors in chemotherapy preparation: implications for patient safety”. Lancet Oncology9 (2017): 1290-1297.
8. Orlowski M and Alvarado M. “Use of barcode verification in chemotherapy preparation”. Journal of Oncology Pharmacy Practice 2 (2020): 352-358.
9. “Safe handling of cytotoxic drugs: guidance for healthcare professionals”. World Health Organization (2016).
10. “Guidance on the preparation and handling of cytotoxic drugs”. Medicines and Healthcare products Regulatory Agency (2018).
11. Fox R and Harrington D. “Robotics in pharmacy: applications in cytotoxicity drug preparation”. Journal of Pharmacy Technology 1 (2021): 42-47.
12. ISO 9001:2015 Quality management systems - Requirements. International Organization for Standardization (2015).
13. Boudrault M and Guérin D. “Best practices for chemotherapy preparation in oncology: National and international perspectives”. Journal of Oncology Pharmacy Practice 4 (2020): 789-796.